Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE).
Duvignaud A, Lhomme E, Onaisi R, Sitta R, Gelley A, Chastang J, Piroth L, Binquet C, Dupouy J, Makinson A, Lefèvre B, Naccache JM, Roussillon C, Landman R, Wallet C, Karcher S, Journot V, Nguyen D, Pistone T, Bouchet S, Lafon ME, Molimard M, Thiébaut R, de Lamballerie X, Joseph JP, Richert L, Saint-Lary O, Djabarouti S, Wittkop L, Anglaret X, Malvy D; Coverage Study Group. Duvignaud A, et al. Among authors: journot v. Clin Microbiol Infect. 2022 Jul;28(7):1010-1016. doi: 10.1016/j.cmi.2022.02.031. Epub 2022 Mar 15. Clin Microbiol Infect. 2022. PMID: 35304280 Free PMC article. Clinical Trial.
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Duvignaud A, Lhomme E, Pistone T, Onaisi R, Sitta R, Journot V, Nguyen D, Peiffer-Smadja N, Crémer A, Bouchet S, Darnaud T, Poitrenaud D, Piroth L, Binquet C, Michel JF, Lefèvre B, Lebeaux D, Lebel J, Dupouy J, Roussillon C, Gimbert A, Wittkop L, Thiébaut R, Orne-Gliemann J, Joseph JP, Richert L, Anglaret X, Malvy D; COVERAGE study group. Duvignaud A, et al. Among authors: journot v. Trials. 2020 Oct 13;21(1):846. doi: 10.1186/s13063-020-04619-1. Trials. 2020. PMID: 33050924 Free PMC article. Clinical Trial.
Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial.
Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé JB, Carrou JL, Kouame GM, Ouattara E, Messou E, Anzian A, Minga A, Gnokoro J, Gouesse P, Emieme A, Toni TD, Rabe C, Sidibé B, Nzunetu G, Dohoun L, Yao A, Kamagate S, Amon S, Kouame AB, Koua A, Kouamé E, Daligou M, Hawerlander D, Ackoundzé S, Koule S, Séri J, Ani A, Dembélé F, Koné F, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatunde N, Bleoué G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Karcher S, Rouzioux C, Kouame A, Assi R, Bakayoko A, Domoua SK, Deschamps N, Aka K, N'Dri-Yoman T, Salamon R, Journot V, Ahibo H, Ouassa T, Menan H, Inwoley A, Danel C, Eholié SP, Anglaret X; Temprano ANRS 12136 Study Group. Badje A, et al. Among authors: journot v. Lancet Glob Health. 2017 Nov;5(11):e1080-e1089. doi: 10.1016/S2214-109X(17)30372-8. Lancet Glob Health. 2017. PMID: 29025631 Free article. Clinical Trial.
Viremia copy-years as a predictive marker of all-cause mortality in HIV-1-infected patients initiating a protease inhibitor-containing antiretroviral treatment.
Chirouze C, Journot V, Le Moing V, Raffi F, Piroth L, Reigadas S, Cassuto JP, Chêne G, Leport C, Hoen B; ANRS CO 08 Aproco-Copilote Study Group. Chirouze C, et al. Among authors: journot v. J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):204-8. doi: 10.1097/QAI.0000000000000416. J Acquir Immune Defic Syndr. 2015. PMID: 25590273
Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996-1997.
Binquet C, Chêne G, Jacqmin-Gadda H, Journot V, Savès M, Lacoste D, Dabis F; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Binquet C, et al. Among authors: journot v. Am J Epidemiol. 2001 Feb 15;153(4):386-93. doi: 10.1093/aje/153.4.386. Am J Epidemiol. 2001. PMID: 11207157
Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy.
Duval X, Journot V, Leport C, Chêne G, Dupon M, Cuzin L, May T, Morlat P, Waldner A, Salamon R, Raffi F; Antiprotease Cohort (APROCO) Study Group. Duval X, et al. Among authors: journot v. Clin Infect Dis. 2004 Jul 15;39(2):248-55. doi: 10.1086/422141. Epub 2004 Jul 1. Clin Infect Dis. 2004. PMID: 15307035
[Public clinical trials: which kind of monitoring should be used?].
Cornu C, Binquet C, Thalamas C, Vigouroux C, Gaillard S, Ginhoux T, Vaz B, Jossan C, Félin A, Sailly A, Gueyffier F, Journot V, Kassaï B. Cornu C, et al. Among authors: journot v. Therapie. 2013 May-Jun;68(3):135-41. doi: 10.2515/therapie/2013032. Epub 2013 Jul 26. Therapie. 2013. PMID: 23886457 French.
Virological failure and drug resistance in West African HIV-infected adults who started ART immediately or deferred ART initiation.
Gabillard D, N'Takpé JB, Chaix ML, Kouame GM, Moh R, Toni TD, Le Carrou J, Karcher S, Badje A, Emieme A, Menan H, Danel C, Anglaret X, Eholié SP; Temprano ANRS 12136 study group. Gabillard D, et al. J Antimicrob Chemother. 2021 Sep 15;76(10):2666-2674. doi: 10.1093/jac/dkab225. J Antimicrob Chemother. 2021. PMID: 34533197 Clinical Trial.
45 results